171 related articles for article (PubMed ID: 31569395)
1. N6-Isopentenyladenosine Inhibits Colorectal Cancer and Improves Sensitivity to 5-Fluorouracil-Targeting FBXW7 Tumor Suppressor.
Fiore D; Piscopo C; Proto MC; Vasaturo M; Dal Piaz F; Fusco BM; Pagano C; Laezza C; Bifulco M; Gazzerro P
Cancers (Basel); 2019 Sep; 11(10):. PubMed ID: 31569395
[TBL] [Abstract][Full Text] [Related]
2. Modified Adenosines Sensitize Glioblastoma Cells to Temozolomide by Affecting DNA Methyltransferases.
Proto MC; Fiore D; Piscopo C; Laezza C; Bifulco M; Gazzerro P
Front Pharmacol; 2022; 13():815646. PubMed ID: 35559231
[TBL] [Abstract][Full Text] [Related]
3. N6-Isopentenyladenosine promoted HeLa cell apoptosis through inhibitions of AKT and transforming growth factor β-activated kinase 1 activation.
Li M; Qi Y; Wei J; Lu L; Zhao X; Zhou L
Tumour Biol; 2017 Mar; 39(3):1010428317695966. PubMed ID: 28345459
[TBL] [Abstract][Full Text] [Related]
4. N6-isopentenyladenosine dual targeting of AMPK and Rab7 prenylation inhibits melanoma growth through the impairment of autophagic flux.
Ranieri R; Ciaglia E; Amodio G; Picardi P; Proto MC; Gazzerro P; Laezza C; Remondelli P; Bifulco M; Pisanti S
Cell Death Differ; 2018 Feb; 25(2):353-367. PubMed ID: 29027991
[TBL] [Abstract][Full Text] [Related]
5. Tumor suppressor Fbxw7 antagonizes WNT signaling by targeting β-catenin for degradation in pancreatic cancer.
Jiang JX; Sun CY; Tian S; Yu C; Chen MY; Zhang H
Tumour Biol; 2016 Oct; 37(10):13893-13902. PubMed ID: 27485116
[TBL] [Abstract][Full Text] [Related]
6. FBXW7 in Cancer: What Has Been Unraveled Thus Far?
Sailo BL; Banik K; Girisa S; Bordoloi D; Fan L; Halim CE; Wang H; Kumar AP; Zheng D; Mao X; Sethi G; Kunnumakkara AB
Cancers (Basel); 2019 Feb; 11(2):. PubMed ID: 30791487
[No Abstract] [Full Text] [Related]
7. FBXW7-mutated colorectal cancer cells exhibit aberrant expression of phosphorylated-p53 at Serine-15.
Li N; Lorenzi F; Kalakouti E; Normatova M; Babaei-Jadidi R; Tomlinson I; Nateri AS
Oncotarget; 2015 Apr; 6(11):9240-56. PubMed ID: 25860929
[TBL] [Abstract][Full Text] [Related]
8. N6-isopentenyladenosine and its analogue N6-benzyladenosine induce cell cycle arrest and apoptosis in bladder carcinoma T24 cells.
Castiglioni S; Casati S; Ottria R; Ciuffreda P; Maier JA
Anticancer Agents Med Chem; 2013 May; 13(4):672-8. PubMed ID: 23094912
[TBL] [Abstract][Full Text] [Related]
9. FBXW7/hCDC4 is a general tumor suppressor in human cancer.
Akhoondi S; Sun D; von der Lehr N; Apostolidou S; Klotz K; Maljukova A; Cepeda D; Fiegl H; Dafou D; Marth C; Mueller-Holzner E; Corcoran M; Dagnell M; Nejad SZ; Nayer BN; Zali MR; Hansson J; Egyhazi S; Petersson F; Sangfelt P; Nordgren H; Grander D; Reed SI; Widschwendter M; Sangfelt O; Spruck C
Cancer Res; 2007 Oct; 67(19):9006-12. PubMed ID: 17909001
[TBL] [Abstract][Full Text] [Related]
10. Antiglioma effects of N6-isopentenyladenosine, an endogenous isoprenoid end product, through the downregulation of epidermal growth factor receptor.
Ciaglia E; Abate M; Laezza C; Pisanti S; Vitale M; Seneca V; Torelli G; Franceschelli S; Catapano G; Gazzerro P; Bifulco M
Int J Cancer; 2017 Feb; 140(4):959-972. PubMed ID: 27813087
[TBL] [Abstract][Full Text] [Related]
11. N6-isopentenyladenosine a new potential anti-angiogenic compound that targets human microvascular endothelial cells in vitro.
Castiglioni S; Romeo V; Casati S; Ottria R; Perrotta C; Ciuffreda P; Maier JAM
Nucleosides Nucleotides Nucleic Acids; 2018; 37(10):533-545. PubMed ID: 30465624
[TBL] [Abstract][Full Text] [Related]
12. Fbxw7 regulates tumor apoptosis, growth arrest and the epithelial-to-mesenchymal transition in part through the RhoA signaling pathway in gastric cancer.
Li H; Wang Z; Zhang W; Qian K; Xu W; Zhang S
Cancer Lett; 2016 Jan; 370(1):39-55. PubMed ID: 26458995
[TBL] [Abstract][Full Text] [Related]
13. Recognition by natural killer cells of N6-isopentenyladenosine-treated human glioma cell lines.
Ciaglia E; Laezza C; Abate M; Pisanti S; Ranieri R; D'alessandro A; Picardi P; Gazzerro P; Bifulco M
Int J Cancer; 2018 Jan; 142(1):176-190. PubMed ID: 28884474
[TBL] [Abstract][Full Text] [Related]
14. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1.
Ishii N; Araki K; Yokobori T; Gantumur D; Yamanaka T; Altan B; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Hosouchi Y; Kuwano H; Shirabe K
Oncotarget; 2017 Dec; 8(68):112636-112646. PubMed ID: 29348852
[TBL] [Abstract][Full Text] [Related]
15. KDM5c Promotes Colon Cancer Cell Proliferation Through the FBXW7-c-Jun Regulatory Axis.
Lin H; Ma N; Zhao L; Yang G; Cao B
Front Oncol; 2020; 10():535449. PubMed ID: 33042830
[TBL] [Abstract][Full Text] [Related]
16. Sensitization of colon cancer cells to cisplatin by Fbxw7 via negative regulation of the Nox1-mTOR pathway.
Huang G; Long K
Pathol Res Pract; 2023 Jul; 247():154479. PubMed ID: 37262995
[TBL] [Abstract][Full Text] [Related]
17. The FBXW7 tumor suppressor inhibits breast cancer proliferation and promotes apoptosis by targeting MTDH for degradation.
Chen X; Li XY; Long M; Wang X; Gao ZW; Cui Y; Ren J; Zhang Z; Liu C; Dong K; Zhang H
Neoplasma; 2018; 65(2):201-209. PubMed ID: 29534580
[TBL] [Abstract][Full Text] [Related]
18. N6-isopentenyladenosine, an endogenous isoprenoid end product, directly affects cytotoxic and regulatory functions of human NK cells through FDPS modulation.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Malfitano AM; D'Alessandro A; Gazzerro P; Vitale M; Carbone E; Bifulco M
J Leukoc Biol; 2013 Dec; 94(6):1207-19. PubMed ID: 23847096
[TBL] [Abstract][Full Text] [Related]
19. Opposing functions of Fbxw7 in keratinocyte growth, differentiation and skin tumorigenesis mediated through negative regulation of c-Myc and Notch.
Ishikawa Y; Hosogane M; Okuyama R; Aoyama S; Onoyama I; Nakayama KI; Nakayama K
Oncogene; 2013 Apr; 32(15):1921-32. PubMed ID: 22665065
[TBL] [Abstract][Full Text] [Related]
20. N6-isopentenyladenosine affects cytotoxic activity and cytokines production by IL-2 activated NK cells and exerts topical anti-inflammatory activity in mice.
Ciaglia E; Pisanti S; Picardi P; Laezza C; Sosa S; Tubaro A; Vitale M; Gazzerro P; Malfitano AM; Bifulco M
Pharmacol Res; 2014 Nov; 89():1-10. PubMed ID: 25063359
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
